IN2014KN02993A - - Google Patents

Info

Publication number
IN2014KN02993A
IN2014KN02993A IN2993KON2014A IN2014KN02993A IN 2014KN02993 A IN2014KN02993 A IN 2014KN02993A IN 2993KON2014 A IN2993KON2014 A IN 2993KON2014A IN 2014KN02993 A IN2014KN02993 A IN 2014KN02993A
Authority
IN
India
Prior art keywords
compounds
modulators
making
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN02993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of IN2014KN02993A publication Critical patent/IN2014KN02993A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
IN2993KON2014 2012-07-17 2013-07-15 IN2014KN02993A (enrdf_load_stackoverflow)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
IN2014KN02993A true IN2014KN02993A (enrdf_load_stackoverflow) 2015-05-08

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2993KON2014 IN2014KN02993A (enrdf_load_stackoverflow) 2012-07-17 2013-07-15

Country Status (39)

Country Link
US (5) US8957104B2 (enrdf_load_stackoverflow)
EP (1) EP2875013B1 (enrdf_load_stackoverflow)
JP (1) JP6106746B2 (enrdf_load_stackoverflow)
KR (1) KR102127939B1 (enrdf_load_stackoverflow)
CN (1) CN104619693B (enrdf_load_stackoverflow)
AR (1) AR091770A1 (enrdf_load_stackoverflow)
AU (1) AU2013291721B2 (enrdf_load_stackoverflow)
BR (1) BR112015000940B1 (enrdf_load_stackoverflow)
CA (1) CA2879104C (enrdf_load_stackoverflow)
CL (1) CL2015000119A1 (enrdf_load_stackoverflow)
CO (1) CO7240378A2 (enrdf_load_stackoverflow)
CR (1) CR20150008A (enrdf_load_stackoverflow)
CY (1) CY1120064T1 (enrdf_load_stackoverflow)
DK (1) DK2875013T3 (enrdf_load_stackoverflow)
DO (1) DOP2015000004A (enrdf_load_stackoverflow)
EA (1) EA026371B8 (enrdf_load_stackoverflow)
ES (1) ES2657912T3 (enrdf_load_stackoverflow)
HR (1) HRP20180061T1 (enrdf_load_stackoverflow)
HU (1) HUE036238T2 (enrdf_load_stackoverflow)
IL (1) IL236448A (enrdf_load_stackoverflow)
IN (1) IN2014KN02993A (enrdf_load_stackoverflow)
JO (1) JO3384B1 (enrdf_load_stackoverflow)
LT (1) LT2875013T (enrdf_load_stackoverflow)
ME (1) ME02996B (enrdf_load_stackoverflow)
MX (1) MX349943B (enrdf_load_stackoverflow)
MY (2) MY198512A (enrdf_load_stackoverflow)
NZ (1) NZ703129A (enrdf_load_stackoverflow)
PE (1) PE20150371A1 (enrdf_load_stackoverflow)
PH (1) PH12015500104A1 (enrdf_load_stackoverflow)
PL (1) PL2875013T3 (enrdf_load_stackoverflow)
PT (1) PT2875013T (enrdf_load_stackoverflow)
RS (1) RS56810B1 (enrdf_load_stackoverflow)
SG (1) SG11201408493WA (enrdf_load_stackoverflow)
SI (1) SI2875013T1 (enrdf_load_stackoverflow)
SM (1) SMT201800115T1 (enrdf_load_stackoverflow)
TW (1) TWI574946B (enrdf_load_stackoverflow)
UY (1) UY34911A (enrdf_load_stackoverflow)
WO (1) WO2014013309A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500096B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
SMT201800115T1 (it) 2012-07-17 2018-03-08 Glaxosmithkline Ip No 2 Ltd Indolo carbonitrili come modulatori selettivi del recettore degli androgeni
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
KR101994922B1 (ko) * 2014-10-16 2019-07-01 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特(成都)生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043651A2 (en) 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
DE69916833T2 (de) * 1998-06-19 2005-04-14 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-verbindungen
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
KR100994169B1 (ko) 2002-05-24 2010-11-15 바이엘 크롭사이언스 아게 티오알킬아민 유도체의 제조방법
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5-h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1-(1h-吲哚-1-基)-3-(4-甲基哌嗪-1-基)-1-苯基丙烷-2-醇衍生物和相关化合物
ATE525354T1 (de) 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
WO2005111042A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
EP1753749B1 (en) 2004-05-03 2014-07-30 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
ES2340180T3 (es) * 2004-06-01 2010-05-31 F.Hoffmann-La Roche Ag 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
SG170783A1 (en) * 2005-07-29 2011-05-30 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
EP2079466B1 (en) * 2006-09-29 2014-01-15 GlaxoSmithKline LLC Substituted indole compounds
CN102131812B (zh) * 2008-08-20 2014-04-09 硕腾有限责任公司 吡咯并[2,3-d]嘧啶化合物
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
PE20121077A1 (es) * 2009-10-15 2012-08-10 Pfizer Compuestos de pirrolo[2,3-d]pirimidina
EP2513114B1 (en) * 2009-12-18 2014-04-02 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
JP6126528B2 (ja) 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System 神経新生促進化合物
CN103384661B (zh) * 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途
SMT201800115T1 (it) * 2012-07-17 2018-03-08 Glaxosmithkline Ip No 2 Ltd Indolo carbonitrili come modulatori selettivi del recettore degli androgeni
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
RS56810B1 (sr) 2018-04-30
IL236448A0 (en) 2015-02-26
US20170073309A1 (en) 2017-03-16
KR20150032333A (ko) 2015-03-25
CN104619693B (zh) 2019-08-13
EP2875013A1 (en) 2015-05-27
US10196353B2 (en) 2019-02-05
MY198512A (en) 2023-09-01
HK1208867A1 (en) 2016-03-18
KR102127939B1 (ko) 2020-06-29
MX349943B (es) 2017-08-21
PE20150371A1 (es) 2015-03-27
JO3384B1 (ar) 2019-03-13
US11299457B2 (en) 2022-04-12
DK2875013T3 (en) 2018-01-22
HUE036238T2 (hu) 2018-06-28
MX2015000825A (es) 2015-07-17
CR20150008A (es) 2015-03-09
EA201492237A1 (ru) 2015-06-30
CA2879104C (en) 2020-08-25
IL236448A (en) 2016-10-31
TWI574946B (zh) 2017-03-21
CL2015000119A1 (es) 2015-04-24
WO2014013309A1 (en) 2014-01-23
EA026371B1 (ru) 2017-03-31
UY34911A (es) 2014-02-28
CY1120064T1 (el) 2018-12-12
JP6106746B2 (ja) 2017-04-05
US20140024694A1 (en) 2014-01-23
AU2013291721B2 (en) 2016-02-25
PL2875013T3 (pl) 2018-06-29
ES2657912T3 (es) 2018-03-07
EA026371B8 (ru) 2017-06-30
CO7240378A2 (es) 2015-04-17
PH12015500104B1 (en) 2015-03-02
SG11201408493WA (en) 2015-02-27
US9533948B2 (en) 2017-01-03
SI2875013T1 (en) 2018-03-30
HRP20180061T1 (hr) 2018-02-23
US20200270210A1 (en) 2020-08-27
AU2013291721A1 (en) 2015-02-26
BR112015000940A2 (pt) 2017-06-27
PH12015500104A1 (en) 2015-03-02
CN104619693A (zh) 2015-05-13
US8957104B2 (en) 2015-02-17
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
JP2015522603A (ja) 2015-08-06
MY173845A (en) 2020-02-24
CA2879104A1 (en) 2014-01-23
US10710963B2 (en) 2020-07-14
AR091770A1 (es) 2015-02-25
US20150080449A1 (en) 2015-03-19
PT2875013T (pt) 2018-02-28
LT2875013T (lt) 2018-02-26
SMT201800115T1 (it) 2018-03-08
DOP2015000004A (es) 2015-03-15
BR112015000940B1 (pt) 2022-05-17
ZA201500096B (en) 2017-07-26
US20190127326A1 (en) 2019-05-02
ME02996B (me) 2018-10-20
EP2875013B1 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
IL273567A (en) Derivatives of ((3a,5p,7a – 3, 7-deoxy-23-amino-24- norchaloane as modulators of FXR/TGR5
PH12018500718A1 (en) Compounds useful as modulators of trpm8
PH12016500968B1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
IN2014KN02993A (enrdf_load_stackoverflow)
MX2021009309A (es) Modulacion de la actividad del complemento.
MY172739A (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
GB201017345D0 (en) Receptor antagonists
IN2015DN00127A (enrdf_load_stackoverflow)
IN2014DN05885A (enrdf_load_stackoverflow)
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
JO3755B1 (ar) تركيبات تستوستيرون
TN2014000136A1 (en) Selective androgen receptor modulators
EP4487913A3 (en) Opioid receptor modulators
IN2015DN01688A (enrdf_load_stackoverflow)
IN2014DN09450A (enrdf_load_stackoverflow)
IN2013MU00848A (enrdf_load_stackoverflow)
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
EP2994542A4 (en) Compositions for ovarian cancer assessment having improved specificity
IN2013MU01113A (enrdf_load_stackoverflow)
IN2014DN10209A (enrdf_load_stackoverflow)
EP3074890A4 (en) Generating resources for support of online services